Overview

Location [1]
22q11.22
Protein [2]
Melanoma antigen preferentially expressed in tumors
Synonyms [1]
CT130, MAPE, OIP4, OIP-4

PRAME is altered in 1.86% of all cancers with lung adenocarcinoma, colon adenocarcinoma, skin squamous cell carcinoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].

PRAME GENIE Cases - Top Diseases

The most common alterations in PRAME are PRAME Mutation (1.56%), PRAME Loss (0.18%), PRAME Amplification (0.16%), PRAME L265V (0.05%), and PRAME P504S (0.04%) [3].

PRAME GENIE Cases - Top Alterations

Significance of PRAME in Diseases

Malignant Solid Tumor +

Acute Myeloid Leukemia +

Ovarian Carcinoma +

Myelodysplastic Syndrome With Excess Blasts-1 +

Myelodysplastic Syndrome With Excess Blasts-2 +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.